Literature DB >> 18593734

Human hallucinogen research: guidelines for safety.

Mw Johnson1, Wa Richards, Rr Griffiths.   

Abstract

There has recently been a renewal of human research with classical hallucinogens (psychedelics). This paper first briefly discusses the unique history of human hallucinogen research, and then reviews the risks of hallucinogen administration and safeguards for minimizing these risks. Although hallucinogens are relatively safe physiologically and are not considered drugs of dependence, their administration involves unique psychological risks. The most likely risk is overwhelming distress during drug action ('bad trip'), which could lead to potentially dangerous behaviour such as leaving the study site. Less common are prolonged psychoses triggered by hallucinogens. Safeguards against these risks include the exclusion of volunteers with personal or family history of psychotic disorders or other severe psychiatric disorders, establishing trust and rapport between session monitors and volunteer before the session, careful volunteer preparation, a safe physical session environment and interpersonal support from at least two study monitors during the session. Investigators should probe for the relatively rare hallucinogen persisting perception disorder in follow-up contact. Persisting adverse reactions are rare when research is conducted along these guidelines. Incautious research may jeopardize participant safety and future research. However, carefully conducted research may inform the treatment of psychiatric disorders, and may lead to advances in basic science.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18593734      PMCID: PMC3056407          DOI: 10.1177/0269881108093587

Source DB:  PubMed          Journal:  J Psychopharmacol        ISSN: 0269-8811            Impact factor:   4.153


  102 in total

1.  Subjective effects and tolerability of the South American psychoactive beverage Ayahuasca in healthy volunteers.

Authors:  J Riba; A Rodríguez-Fornells; G Urbano; A Morte; R Antonijoan; M Montero; J C Callaway; M J Barbanoj
Journal:  Psychopharmacology (Berl)       Date:  2001-02       Impact factor: 4.530

2.  Comparison of psilocin with psilocybin, mescaline and LSD-25.

Authors:  A B WOLBACH; E J MINER; H ISBELL
Journal:  Psychopharmacologia       Date:  1962

3.  In vivo and in vitro chromosomal damage induced by LSD-25.

Authors:  M M Cohen; K Hirschhorn; W A Frosch
Journal:  N Engl J Med       Date:  1967-11-16       Impact factor: 91.245

4.  Human psychopharmacology of hoasca, a plant hallucinogen used in ritual context in Brazil.

Authors:  C S Grob; D J McKenna; J C Callaway; G S Brito; E S Neves; G Oberlaender; O L Saide; E Labigalini; C Tacla; C T Miranda; R J Strassman; K B Boone
Journal:  J Nerv Ment Dis       Date:  1996-02       Impact factor: 2.254

5.  Dose-response study of N,N-dimethyltryptamine in humans. II. Subjective effects and preliminary results of a new rating scale.

Authors:  R J Strassman; C R Qualls; E H Uhlenhuth; R Kellner
Journal:  Arch Gen Psychiatry       Date:  1994-02

6.  Dose-response study of N,N-dimethyltryptamine in humans. I. Neuroendocrine, autonomic, and cardiovascular effects.

Authors:  R J Strassman; C R Qualls
Journal:  Arch Gen Psychiatry       Date:  1994-02

7.  Effects of the hallucinogen psilocybin on covert orienting of visual attention in humans.

Authors:  E Gouzoulis-Mayfrank; B Thelen; S Maier; K Heekeren; K-A Kovar; H Sass; M Spitzer
Journal:  Neuropsychobiology       Date:  2002       Impact factor: 2.328

8.  Transient reinforcing effects of phenylisopropylamine and indolealkylamine hallucinogens in rhesus monkeys.

Authors:  W E Fantegrossi; J H Woods; G Winger
Journal:  Behav Pharmacol       Date:  2004-03       Impact factor: 2.293

Review 9.  Human hallucinogenic drug research in the United States: a present-day case history and review of the process.

Authors:  R J Strassman
Journal:  J Psychoactive Drugs       Date:  1991 Jan-Mar

10.  Differential tolerance to biological and subjective effects of four closely spaced doses of N,N-dimethyltryptamine in humans.

Authors:  R J Strassman; C R Qualls; L M Berg
Journal:  Biol Psychiatry       Date:  1996-05-01       Impact factor: 13.382

View more
  168 in total

1.  Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness.

Authors:  Katherine A MacLean; Matthew W Johnson; Roland R Griffiths
Journal:  J Psychopharmacol       Date:  2011-09-28       Impact factor: 4.153

2.  LSD enhances the emotional response to music.

Authors:  M Kaelen; F S Barrett; L Roseman; R Lorenz; N Family; M Bolstridge; H V Curran; A Feilding; D J Nutt; R L Carhart-Harris
Journal:  Psychopharmacology (Berl)       Date:  2015-08-11       Impact factor: 4.530

Review 3.  Psychedelic medicine: a re-emerging therapeutic paradigm.

Authors:  Kenneth W Tupper; Evan Wood; Richard Yensen; Matthew W Johnson
Journal:  CMAJ       Date:  2015-09-08       Impact factor: 8.262

4.  Psilocybin disrupts sensory and higher order cognitive processing but not pre-attentive cognitive processing-study on P300 and mismatch negativity in healthy volunteers.

Authors:  Anna Bravermanová; Michaela Viktorinová; Filip Tylš; Tomáš Novák; Renáta Androvičová; Jakub Korčák; Jiří Horáček; Marie Balíková; Inga Griškova-Bulanova; Dominika Danielová; Přemysl Vlček; Pavel Mohr; Martin Brunovský; Vlastimil Koudelka; Tomáš Páleníček
Journal:  Psychopharmacology (Berl)       Date:  2018-01-05       Impact factor: 4.530

5.  A sub-set of psychoactive effects may be critical to the behavioral impact of ketamine on cocaine use disorder: Results from a randomized, controlled laboratory study.

Authors:  E Dakwar; E V Nunes; C L Hart; M C Hu; R W Foltin; F R Levin
Journal:  Neuropharmacology       Date:  2018-01-05       Impact factor: 5.250

6.  The Challenging Experience Questionnaire: Characterization of challenging experiences with psilocybin mushrooms.

Authors:  Frederick S Barrett; Matthew P Bradstreet; Jeannie-Marie S Leoutsakos; Matthew W Johnson; Roland R Griffiths
Journal:  J Psychopharmacol       Date:  2016-11-17       Impact factor: 4.153

7.  Does human language limit translatability of clinical and preclinical addiction research?

Authors:  Harriet de Wit; David H Epstein; Kenzie L Preston
Journal:  Neuropsychopharmacology       Date:  2018-05-17       Impact factor: 7.853

8.  Cognitive effects of intramuscular ketamine and oral triazolam in healthy volunteers.

Authors:  Lawrence P Carter; Bethea A Kleykamp; Roland R Griffiths; Miriam Z Mintzer
Journal:  Psychopharmacology (Berl)       Date:  2012-10-25       Impact factor: 4.530

9.  Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences.

Authors:  Theresa M Carbonaro; Matthew P Bradstreet; Frederick S Barrett; Katherine A MacLean; Robert Jesse; Matthew W Johnson; Roland R Griffiths
Journal:  J Psychopharmacol       Date:  2016-08-30       Impact factor: 4.153

Review 10.  The default-mode, ego-functions and free-energy: a neurobiological account of Freudian ideas.

Authors:  R L Carhart-Harris; K J Friston
Journal:  Brain       Date:  2010-02-28       Impact factor: 13.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.